AVITA Medical
Logotype for AVITA Medical Inc

AVITA Medical (RCEL) investor relations material

AVITA Medical Investor update summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for AVITA Medical Inc
Investor update summary11 Nov, 2026

Q3 2026 performance

  • Revenue was $26.1M, up 53% YoY and 20% QoQ; U.S. RECELL revenue reached $22.4M, up 21% QoQ, while RECELL and Cohealyx each grew 20% QoQ.

  • Gross margin was 84%, up 270 bps YoY and 210 bps QoQ; RECELL gross margin was 88.4%.

  • Operating expenses were $24.6M, flat QoQ; net loss was $6.2M, down 53% YoY and 19.5% QoQ.

  • Cash use was $0.6M, down from $3.2M in Q2; Q1 included $9.9M of one-time payments.

  • Cash balance was $10.5M; after reaching $85M in trailing 12-month revenue, a $10M draw under the Perceptive facility brought pro forma cash to ~$21M.

Revenue and outlook

  • FY26 revenue guidance was raised for a second consecutive time to $92M-$94M from $86M-$89M; the midpoint implies ~30% growth versus 2025.

  • Guidance implies Q4 revenue of $24.9M-$26.9M; elevated U.S. burn activity added ~$1M to Q3 revenue.

  • Q4 2026 cash flow breakeven remains expected; Q1 2027 cash use is expected from one-offs, including a $3M Regenity payment, followed by cash generation.

  • Operating plans target 20%-25% growth in subsequent years, with quarterly growth expected through 2027.

  • RECELL gross margin outlook was 85%-89%, with overall gross margin outlook of 82%-84%; operating expenses are expected to remain relatively flat with modest increases.

Commercial, reimbursement and adoption

  • CMS finalized national Medicare physician payment for RECELL procedures and simplified CPT coding, effective Jan. 1, 2027; revisions consolidate eight family codes to four and clarify outpatient and ASC payments.

  • New coding bundles harvest, preparation and application, uses 100 sq. cm. increments, removes manual-versus-automated preparation distinctions and restores pediatric reporting by body-surface-area percentage.

  • 25 accounts use all three products to some degree and 70-75 accounts use two; addressable opportunities are $600M-$650M for RECELL, ~$450M for Cohealyx and $200M-$250M for PermeaDerm.

  • RECELL remains underpenetrated, including in burns; trauma and surgical wound expansion is supported by clinical and economic education and RECELL GO mini. NTAP expiry was expected to have no impact on adoption.

  • RECELL GO expanded from Western Australia to leading children's hospitals in Victoria and Queensland; commercial activity was reported in the U.K. and Germany, alongside progress in Japan, Europe and eastern Australia.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next AVITA Medical earnings date

Logotype for AVITA Medical Inc
Q4 202611 Feb, 2027
AVITA Medical
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next AVITA Medical earnings date

Logotype for AVITA Medical Inc
Q4 202611 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

AVITA Medical Inc is a regenerative medicine company that develops and markets therapeutic solutions for skin restoration. Its primary product is a spray-on skin system used for treating burns, wounds, and dermatological conditions. The company operates in North America and internationally through partnerships and direct sales. AVITA Medical Inc is headquartered in Valencia, California, and its shares are listed on the NASDAQ.